Company news
Cardiol Therapeutics Inc. news in 2022
Cardiol Therapeutics Inc.'s news releases, calls and decks from 2022, newest first.
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis
December 16, 2022
Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis
December 12, 2022
Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis
November 7, 2022
Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases
October 25, 2022
Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis
October 3, 2022
Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America
September 28, 2022
Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis
August 3, 2022
Cardiol Therapeutics Reports Results of 2022 Annual General Meeting
June 29, 2022
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4: 30 P.M. EDT
June 27, 2022
Cardiol Therapeutics Announces At-The-Market Equity Offering Program
June 9, 2022
Market Movers. Today's Top Stock Picks For New & Trending Opportunities
May 27, 2022
Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors
May 19, 2022
Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis
May 17, 2022
Cardiol Therapeutics Announces Year-End 2021 Update on Operations
March 24, 2022
Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit
March 22, 2022
Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors
March 15, 2022
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial
March 1, 2022
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board
January 19, 2022
Decks in 2022
- Investor Presentation (April 2022)
Investor deck · 32 slides · April 2022
- Investor Presentation (January 2022)
Investor deck · 31 slides · January 2022